Related Experiment Video
Updated: Jun 24, 2026

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
Published on: May 2, 2011
Guillain-Barré syndrome following coronavirus disease vaccine: First report from Nepal
Prajjwol Luitel1, Bibek Poudel1, Devansh Upadhyay1
1Tribhuvan University Institute of Medicine, Kathmandu, Nepal.
Abstract:
ChAdOx1 nCoV-19 is an effective and well-tolerated coronavirus disease 2019 vaccine. However, rare cases of serious adverse events have been reported with it. We report a patient who did not have active or prior coronavirus disease 2019 infection, who developed Guillain-Barré syndrome 7 days following the first dose of ChAdOx1 nCoV-19 vaccination. He was treated with intravenous immunoglobulin, with stabilization of the disease. Proper monitoring and prompt reporting of such cases are required to ensure the safety of the vaccine.
More Related Videos
06:32Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
07:30A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
Published on: November 9, 2017
Related Concept Videos
Cross-reactivity
Vaccines
Botulism
Viral Meningitis
Poliomyelitis
Arboviral Encephalitis